Pheast Therapeutics announced the presentation of new preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage "don't eat me" signal on cancer cells.
Cencora bolstered the support it can offer to pharmaceutical companies through the addition of Public Health Expertise (PHE), a France-based life sciences consulting firm that specialises in market access, health economics and outcomes research.
PacBio announced the Vega system, the company’s first benchtop long-read sequencing platform, delivering all the functionality of the Revio system into a compact, lower-throughput benchtop platform.
Given the success of nasal drug-delivery products relies on balancing formulation and device selection, Eric Kaneps at Renaissance Lakewood, LLC explains the importance of partnerships and collaborations drug development and manufacturing.
Aptamer Group announced that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery vehicles.
Cherwell is to highlight its range of products for environmental monitoring and process validation in sterile medicinal product manufacturing and how these complement other products within its parent company AnalytiChem’s Life Science segment.
Sonrai is working to bring its innovative cloud-based AI technology to the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital (MGH), enabling vast and complex data for more meaningful insights.
Bespak and Orbia Advance Corporation announced a collaboration intended to accelerate the transition to climate-friendly inhalers utilising Orbia Fluor & Energy Materials’ low global warming potential propellant known as Zephex 152a.
